Pricing Log in Create free account
Friday 6 November 2026 Export INSM’s income statement to Excel — free account

Insmed, Inc.

INSM Healthcare Biotechnology

Insmed, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $606.4 million, up 66.7% from fiscal 2024.

Revenue
+268.4%
EPS
+73.8%
Free cash flow
+81.1%
Total debt
+0.27%

Quarter to September 2026, against a year earlier

112.70 3.94 +3.62%
Market cap
$23.9B
P/E
0.0×
Fwd P/E
−64.6×
Dividend yield
—
F-score
4/9
Altman Z
9.29
Beneish M
−1.90
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Insmed, Inc. 8-K filed Feb 22, 2024

Period ended Feb 22, 2024 · Filed · accepted 7:58 AM ET · Document on sec.gov · Filing index

1.01 Entry into a material definitive agreement; 1.02 Termination of a material definitive agreement; 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits

Nothing in this filing raised a red flag, and we have no summary of it. The items it reports are listed above; the document itself is on sec.gov.

Read the filing on sec.gov The press release